<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>23</Volume>
				<Issue>7</Issue>
				<PubDate PubStatus="epublish">
					<Year>2022</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2497</FirstPage>
			<LastPage>2505</LastPage>
			<ELocationID EIdType="pii">90205</ELocationID>
			
<ELocationID EIdType="doi">10.31557/APJCP.2022.23.7.2497</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Nigel P</FirstName>
					<LastName>Murray</LastName>
<Affiliation>CTC Unit, Faculty of Medicine, University Finis Terrae, Santiago, Chile.</Affiliation>
<Identifier Source="ORCID">0000-0001-8154-8550</Identifier>

</Author>
<Author>
					<FirstName>Socrates </FirstName>
					<LastName>Aedo</LastName>
<Affiliation>Faculty of Medicine, University Finis Terrae
Santiago, Chile.</Affiliation>
<Identifier Source="ORCID">0000-0001-5567-3374</Identifier>

</Author>
<Author>
					<FirstName>Cynthia </FirstName>
					<LastName>Fuentealba</LastName>
<Affiliation>Urology Service, Hospital de Carabineros de Chile, Santiago, Chile.</Affiliation>
<Identifier Source="ORCID">0000-000304100-6997</Identifier>

</Author>
<Author>
					<FirstName>Eduardo </FirstName>
					<LastName>Reyes</LastName>
<Affiliation>Faculty of Medicine, University Diego
Portales Santiago, Chile.</Affiliation>
<Identifier Source="ORCID">0000-0001-8430-3030</Identifier>

</Author>
<Author>
					<FirstName>Anibal </FirstName>
					<LastName>Salazar</LastName>
<Affiliation>Department of Urology, Hospital de Carabineros de Chile, Santiago, Chile.</Affiliation>
<Identifier Source="ORCID">0000-0001-9319-4219</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2022</Year>
					<Month>04</Month>
					<Day>05</Day>
				</PubDate>
			</History>
		<Abstract>Introduction: To determine if there was an association of the ALC (absolute lymphocyte count) and LCP (lymphocytopenia) with the expression of MMP-2 in bone marrow micro-metastasis, the changes occurring during follow-up and association with biochemical failure. Methods and patients: One month after surgery blood and bone marrow samples were taken to determine the presence of micro-metastasis, the presence of circulating prostate cells (CPCs) and ALC. CPCs and micro-metastasis were detected using immunocytochemistry and MMP-2 expression determined in micro-metastasis. Only men positive for micro-metastasis participated in the study. At end follow blood was taken for serum PSA, ALC and CPCs, if the ALC decreased by more than 10% bone marrow sampling was repeated and MMP-2 expression determined, similarly for men with BF. Men who had stable ALCs had an end of study evaluation of the bone marrow. Results: 402 men underwent radical prostatectomy, one month post surgery 79 men were positive for only bone marrow micro-metastasis and formed the study group; of whom 36/79 (45%) underwent BF. Clinical pathological findings were not significantly different between men with or without BF. In men with BF the ALC was significantly lower one-month post surgery. The 5 and 10 year Kaplan-Meier survival was 100% at 5-years and 65% at 10-years for the whole cohort. Men without BF had stable ALCs. A decrease of &gt;10% in the ALC was associated with increasing MMP-2 expression in the micro-metastasis and surrounding stromal tissue, the appearance of CPCs 6-12 months later and BF. Conclusions: the immune host-tumour cell interaction in the microenvironment is dynamic and changes with time. A decreasing ALC may be a valuable marker in identifying men with high risk of BF and changes in immune mediated dormancy before the PSA rises.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">minimal residual disease</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Immune function</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">lymphocytopenia</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prostate Cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">biochemical failure</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_90205_13a98d06cfbcd86d5dfbb1af72783911.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
